Details of the Drug Combinations

General Information of This Drug (ID: DMYCXKL)

• Drug Name: Capmatinib (DMYCXKL)
• Synonyms: 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O

Indication

Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Approved [1]; Hepatocellular carcinoma; ICD 11: 2C12.02; Status: Phase 2 [2]; Recurrent glioblastoma; ICD 11: 2A00.00; Status: Phase 1 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
EGF816 + Capmatinib	DCAP2E0	EGF816	Non Small Cell Lung Cancer	[4]
Erlotinib + Capmatinib	DCBLDLO	Erlotinib	Recurrent Non-small Cell Lung Cancer	[5]
Everolimus + Capmatinib	DCDOT50	Everolimus	Pediatric Cancer	[6]
Gefitinib + Capmatinib	DC4BJ6N	Gefitinib	Non-small Cell Lung Cancer	[7]
HKI-272 + Capmatinib	DCTKV0R	HKI-272	Metastatic Breast Cancer	[8]
Trametinib + Capmatinib	DC0QVG2	Trametinib	Metastatic Lung Non-Small Cell Carcinoma	[9]
Osimertinib + Capmatinib	DCRDJR2	Osimertinib	Advanced Solid Tumors Which Are cMET-dependent	[10]
Osimertinib + Capmatinib	DC1S8C7	Osimertinib	Carcinoma, Non-Small-Cell Lung	[11]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031741)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT02335944) Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
• [5] ClinicalTrials.gov (NCT01911507) INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
• [6] ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
• [7] ClinicalTrials.gov (NCT01610336) A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
• [8] ClinicalTrials.gov (NCT05243641) Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
• [9] ClinicalTrials.gov (NCT05435846) Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
• [10] ClinicalTrials.gov (NCT03040973) Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
• [11] ClinicalTrials.gov (NCT04816214) Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy